Cargando…

The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19: A retrospective cohort study

BACKGROUND: Huashibaidu Formula (HSBD) for the COVID-19 treatment has been supported by the China's Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. However, it is not clear whether HSBD can improve blood oxygen saturation and when it should be used with conventional therapies....

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Yibai, Tian, Yaxin, Ma, Yan, Liu, Bin, Ruan, Lianguo, Lu, Cheng, Huang, Luqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier GmbH. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641428/
https://www.ncbi.nlm.nih.gov/pubmed/34929564
http://dx.doi.org/10.1016/j.phymed.2021.153868
_version_ 1784609490623004672
author Xiong, Yibai
Tian, Yaxin
Ma, Yan
Liu, Bin
Ruan, Lianguo
Lu, Cheng
Huang, Luqi
author_facet Xiong, Yibai
Tian, Yaxin
Ma, Yan
Liu, Bin
Ruan, Lianguo
Lu, Cheng
Huang, Luqi
author_sort Xiong, Yibai
collection PubMed
description BACKGROUND: Huashibaidu Formula (HSBD) for the COVID-19 treatment has been supported by the China's Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. However, it is not clear whether HSBD can improve blood oxygen saturation and when it should be used with conventional therapies. PURPOSE: To access the effect of HSBD combined with conventional treatment on blood oxygen saturation of COVID-19 patients. METHODS: A single-center retrospective cohort study was conducted to collect the confirmed severe COVID-19 patients’ information, treated by the National Traditional Chinese Medicine Medical Team at the Jinyintan hospital between January 24 and March 31, 2020. According to whether HSBD was used during hospitalization, participants were separated into the conventional treatment group and the HSBD group (HSBD and conventional treatment). The primary observation indicators included the time for relieving blood oxygen saturation and the improvement ratio of blood oxygen saturation in each group. RESULTS: Of 111 patients with severe COVID-19, 53.2% (59/111) received HSBD, and 46.8% (52/111) only received conventional treatment, respectively. No statistically significant difference was found in image, clinical symptoms, and past medical history between the two groups (p > 0.05). Notably, the median time for relieving blood oxygen saturation in the conventional treatment group was 11 days (IQR, 8–14.25), while that in the HSBD group was only 6 days (IQR, 3.25–10.75), which was significantly shortened by 4.09 days (95%CI, 2.07–6.13; p= 0.0001), compared with the conventional treatment group. After repeated measurement design analysis, the main effect within times (p< 0.001) and the main effect were significantly different under the oxygen saturation dimension between two groups (p= 0.004). However, time and group interaction were observed no significant difference (p= 0.094). After 14 days of treatment, the improvement ratio of the HSBD group over the conventional treatment group was 1.20 (95%CI, 0.89–1.61). CONCLUSION: For severe COVID-19 patients, the HSBD has a tendency to shorten the time for relieving blood oxygen saturation. After taking a course of HSBD, the effect can be more obvious.
format Online
Article
Text
id pubmed-8641428
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier GmbH.
record_format MEDLINE/PubMed
spelling pubmed-86414282021-12-03 The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19: A retrospective cohort study Xiong, Yibai Tian, Yaxin Ma, Yan Liu, Bin Ruan, Lianguo Lu, Cheng Huang, Luqi Phytomedicine Original Article BACKGROUND: Huashibaidu Formula (HSBD) for the COVID-19 treatment has been supported by the China's Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. However, it is not clear whether HSBD can improve blood oxygen saturation and when it should be used with conventional therapies. PURPOSE: To access the effect of HSBD combined with conventional treatment on blood oxygen saturation of COVID-19 patients. METHODS: A single-center retrospective cohort study was conducted to collect the confirmed severe COVID-19 patients’ information, treated by the National Traditional Chinese Medicine Medical Team at the Jinyintan hospital between January 24 and March 31, 2020. According to whether HSBD was used during hospitalization, participants were separated into the conventional treatment group and the HSBD group (HSBD and conventional treatment). The primary observation indicators included the time for relieving blood oxygen saturation and the improvement ratio of blood oxygen saturation in each group. RESULTS: Of 111 patients with severe COVID-19, 53.2% (59/111) received HSBD, and 46.8% (52/111) only received conventional treatment, respectively. No statistically significant difference was found in image, clinical symptoms, and past medical history between the two groups (p > 0.05). Notably, the median time for relieving blood oxygen saturation in the conventional treatment group was 11 days (IQR, 8–14.25), while that in the HSBD group was only 6 days (IQR, 3.25–10.75), which was significantly shortened by 4.09 days (95%CI, 2.07–6.13; p= 0.0001), compared with the conventional treatment group. After repeated measurement design analysis, the main effect within times (p< 0.001) and the main effect were significantly different under the oxygen saturation dimension between two groups (p= 0.004). However, time and group interaction were observed no significant difference (p= 0.094). After 14 days of treatment, the improvement ratio of the HSBD group over the conventional treatment group was 1.20 (95%CI, 0.89–1.61). CONCLUSION: For severe COVID-19 patients, the HSBD has a tendency to shorten the time for relieving blood oxygen saturation. After taking a course of HSBD, the effect can be more obvious. The Authors. Published by Elsevier GmbH. 2022-01 2021-12-03 /pmc/articles/PMC8641428/ /pubmed/34929564 http://dx.doi.org/10.1016/j.phymed.2021.153868 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Xiong, Yibai
Tian, Yaxin
Ma, Yan
Liu, Bin
Ruan, Lianguo
Lu, Cheng
Huang, Luqi
The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19: A retrospective cohort study
title The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19: A retrospective cohort study
title_full The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19: A retrospective cohort study
title_fullStr The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19: A retrospective cohort study
title_full_unstemmed The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19: A retrospective cohort study
title_short The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19: A retrospective cohort study
title_sort effect of huashibaidu formula on the blood oxygen saturation status of severe covid-19: a retrospective cohort study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641428/
https://www.ncbi.nlm.nih.gov/pubmed/34929564
http://dx.doi.org/10.1016/j.phymed.2021.153868
work_keys_str_mv AT xiongyibai theeffectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT tianyaxin theeffectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT mayan theeffectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT liubin theeffectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT ruanlianguo theeffectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT lucheng theeffectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT huangluqi theeffectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT theeffectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT xiongyibai effectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT tianyaxin effectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT mayan effectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT liubin effectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT ruanlianguo effectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT lucheng effectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT huangluqi effectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy
AT effectofhuashibaiduformulaonthebloodoxygensaturationstatusofseverecovid19aretrospectivecohortstudy